Here's Why Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Is Among the Best Diabetes Stocks to Buy Under $10
Executive Reshuffles: WELL, SLG and LXRX
Express News | Lexicon Appoints Scott Coiante as Chief Financial Officer
Press Release: Lexicon Appoints Scott Coiante as Chief Financial Officer
Private Equity Firms Account for 47% of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Ownership, While Institutions Account for 33%
Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX), Arcutis Biotherapeutics (ARQT) and Viking Therapeutics (VKTX)
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Lnova : Oh wait fda rejected?
Lnova :
Jaguar8 OP Lnova : CRL
Lnova Jaguar8 OP : Gotcha. But Lex is discontinuing it? They are scrapping it?
Jaguar8 OP Lnova : I think that was their decision after the CRL.
View more comments...